Home > Insider Trading > Filing (0001209191-21-010697)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1557290	A Stuart Arbuckle	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Evp, Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-02-11	4,356	$210.39	62,500	No	4	S	Direct
Common Stock	Disposition	2021-02-11	600	$211.19	61,900	No	4	S	Direct
Common Stock	Disposition	2021-02-11	200	$212.10	61,700	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	140	Indirect	401(k)

Footnotes

Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $210.39 (range $209.85 to $210.83).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $211.19 (range $210.86 to $211.66).
Open market sales reported on this line occurred at a weighted average price of $212.10 (range $211.99 to $212.21).